Gottlieb: New Office Of Drug Evaluation Science Will Change Drug Review

By David Roza / January 8, 2019 at 6:41 PM
FDA is setting up a new Office of Drug Evaluation Science (ODES) that will act as a centralized point of information for various performance metrics and provide more predictable and efficient assessment of safety data, FDA Commissioner Scott Gottlieb announced Tuesday (Jan. 8). He said the new office is part of a broader effort to “change the whole contours” of how FDA reviews drugs by moving towards standardized review methods. Gottlieb said via teleconference at the J.P. Morgan Healthcare Conference...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.